VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | BTK inhibitors in CLL

Florence Cymbalista, MD, of Hôpital Avicenne, Bobigny, France, explores clinical trials evaluating the use of second generation BTK inhibitors such as zanubrutinib and acalabrutinib for chronic lymphocytic leukemia (CLL), and their potential benefits over ibrutinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter